Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Inclusion Criteria: 1. Age ≥18, male or female. 2. Patients must provide written informed consent to participate in the study. 3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th). 4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R). 5. Patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response. 6. ECOG score 0-1 7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given concurrent chemoradiotherapy 3 months after targeted therapy Exclusion Criteria: 1. Patients progress in 3 months after almonertinib treatment 2. Patient can't tolerate radiotherapy or targeted therapy 3. Pregnant or nursing women